Walter joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Walter joined Transave in 2002 and served as Chief Technology Officer. Walter has over 25 years’ experience utilizing nanoparticle drug delivery systems for multiple routes of administration including inhalation and has authored 80 scientific publications and U.S. patent applications. Prior to Transave, Walter spent 15 years with The Liposome Company (later a part of Elan Drug Delivery), where he was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development, and launch of the company’s two commercial products Abelcet® and Myocet®. As part of Elan’s Drug Delivery Division, Walter played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Walter received his bachelor and doctoral degrees in Biophysical Chemistry from the University of Virginia, where he studied liposomes as model membrane systems.